Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve blood glucose control when combined with diet and exercise.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory compliance across multiple regions.

Maysiglu (sitagliptin) is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, targeting glucose regulation pathways. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial blood glucose levels as part of diet and exercise. - Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to metformin, sulfonylureas, or insulin. - HbA1c reduction: helps patients achieve target HbA1c values, improving long‑term diabetes management.

Sitagliptin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Upper respiratory tract infection: cough and sore throat.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain indicating pancreatic inflammation. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: rare blistering skin disorder.

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: evaluate kidney function and adjust therapy in severe renal disease. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Pancreatitis risk: monitor patients for persistent abdominal pain and elevated enzymes. - Cardiovascular status: use cautiously in patients with a history of heart failure. - Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Sitagliptin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels. - Insulin or sulfonylureas: combined use can increase risk of hypoglycaemia. - Rifampin: potent inducer that may lower sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of sitagliptin. - Warfarin: monitor INR as sitagliptin may alter anticoagulant effect. - Digoxin: observe for possible changes in serum concentrations.